{"id":16318,"date":"2022-02-25T19:22:17","date_gmt":"2022-02-25T13:52:17","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=16318"},"modified":"2022-03-10T10:21:29","modified_gmt":"2022-03-10T04:51:29","slug":"asco-renal-cell-carcinoma","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/asco-renal-cell-carcinoma","title":{"rendered":"ASCO GU 2022: Renal Cell Carcinoma Highlights"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><strong>Phase II study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma<\/strong><\/h2>\n\n\n\n<p>Based on the findings from the Phase II study (NCT04022343), neoadjuvant cabozantinib was safe and induced a reduction in tumor size in all patients with locally advanced nonmetastatic ccRCC. According to the results from the analysis, 17 patients with biopsy-proven <a href=\"https:\/\/www.delveinsight.com\/report-store\/clear-cell-renal-cell-carcinoma-ccrcc-epidemiology-forecast\">clear-cell RCC<\/a> were treated with neoadjuvant cabozantinib at a starting dose of 60 mg once per day for 12 weeks.&nbsp;<\/p>\n\n\n\n<p>The results of this investigation revealed that all of the patients&#8217; tumors had shrunk. Five patients (29.4%) experienced a partial response, while 12 patients had stable disease. <strong>The patients who were given cabozantinib did not experience disease progression.<\/strong> The original kidney tumor was shrunk by a median of 23%. Cabozantinib was clinically active and safe in the neoadjuvant setting in patients with locally advanced nonmetastatic clear-cell RCC.<\/p>\n\n\n\n<p><strong>Analyst opinion: <\/strong>A larger clinical trial is needed to further establish the role of presurgical treatment in <a href=\"https:\/\/www.delveinsight.com\/report-store\/renal-cell-carcinoma-market\">Renal Cell Carcinoma<\/a>. This will allow us to understand the long-term role of those treatments. Considering that researchers have already witnessed the increased response rates with Cabozantinib in the metastatic setting and the drug has now shown a safe response in the neoadjuvant setting, we look forward to some exciting data in late phase trial as well.<\/p>\n\n\n\n<p>Moreover, we also know that Neoadjuvant treatment is well established in different solid tumors such as breast cancer, gastrointestinal cancers, and others, and now it\u2019s time for Cabozantinib to enter this area with high unmet need for Renal Cell Carcinoma patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-positive-interim-results-from-the-phase-i-study-of-aro-hif2-to-silence-hif2-alpha-in-patients-with-advanced-ccrenal-cell-carcinoma-arohif21001\"><strong>Positive Interim results from the Phase I study of ARO-HIF2 to silence HIF2-alpha in patients with advanced ccRenal Cell Carcinoma (AROHIF21001)<\/strong><\/h2>\n\n\n\n<p><strong>Arrowhead Pharmaceuticals<\/strong> announced the positive interim results from AROHIF21001 (NCT04169711), a Phase Ib dose-finding clinical study of ARO-HIF2 being developed as a treatment for patients with clear cell renal cell carcinoma (ccRCC). According to the results presented at the ASCO GU symposium, ARO-HIF2 provides initial proof of target engagement based on reductions in hypoxia-inducible factor-2 alpha (HIF2\u03b1) expression, and the safety profile of HIF-2 was well tolerated. From the efficacy point of view, the disease control rate (DCR) in all the three cohorts was <strong>39%<\/strong>. With the data cut off as <strong>December 1, 2021,<\/strong> the ORR was <strong>8%,<\/strong> with one patient in Cohort 2 and one patient in Cohort 3 achieving a partial response in the defined criteria.&nbsp; From the safety point of view, ARO-HIF2 was generally well-tolerated in patients. To draw the inference, the interim safety and efficacy results of ARO-HIF2 are promising to treat patients with advanced ccRCC, and there is a space in the market for such assets.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Phase II study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma Based on the findings from the Phase II study (NCT04022343), neoadjuvant cabozantinib was safe and induced a reduction in tumor size in all patients with locally advanced nonmetastatic ccRCC. According to the results from the analysis, 17 patients [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":16330,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[17537,19114,427,854],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-16318","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-asco","tag-asco-gu-2022","tag-oncology","tag-renal-cell-carcinoma","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Renal Cell Carcinoma Abstracts: ASCO GU 2022<\/title>\n<meta name=\"description\" content=\"Arrowhead Pharmaceuticals, Bristol Myers Squibb and Merck presented some early phase results and data from already approved therapies\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/asco-renal-cell-carcinoma\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Renal Cell Carcinoma Abstracts: ASCO GU 2022\" \/>\n<meta property=\"og:description\" content=\"Arrowhead Pharmaceuticals, Bristol Myers Squibb and Merck presented some early phase results and data from already approved therapies\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/asco-renal-cell-carcinoma\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-25T13:52:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-10T04:51:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/25192143\/Renal-Cell-Carcinoma-Highlights-ASCO.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Renal Cell Carcinoma Abstracts: ASCO GU 2022","description":"Arrowhead Pharmaceuticals, Bristol Myers Squibb and Merck presented some early phase results and data from already approved therapies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/asco-renal-cell-carcinoma","og_locale":"en_US","og_type":"article","og_title":"Renal Cell Carcinoma Abstracts: ASCO GU 2022","og_description":"Arrowhead Pharmaceuticals, Bristol Myers Squibb and Merck presented some early phase results and data from already approved therapies","og_url":"https:\/\/www.delveinsight.com\/blog\/asco-renal-cell-carcinoma","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-02-25T13:52:17+00:00","article_modified_time":"2022-03-10T04:51:29+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/25192143\/Renal-Cell-Carcinoma-Highlights-ASCO.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/asco-renal-cell-carcinoma","url":"https:\/\/www.delveinsight.com\/blog\/asco-renal-cell-carcinoma","name":"Renal Cell Carcinoma Abstracts: ASCO GU 2022","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/asco-renal-cell-carcinoma#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/asco-renal-cell-carcinoma#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/25192143\/Renal-Cell-Carcinoma-Highlights-ASCO.png","datePublished":"2022-02-25T13:52:17+00:00","dateModified":"2022-03-10T04:51:29+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/90e3f864ebcfcaa34b1be0e9ae5909e1"},"description":"Arrowhead Pharmaceuticals, Bristol Myers Squibb and Merck presented some early phase results and data from already approved therapies","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/asco-renal-cell-carcinoma"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/asco-renal-cell-carcinoma#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/25192143\/Renal-Cell-Carcinoma-Highlights-ASCO.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/25192143\/Renal-Cell-Carcinoma-Highlights-ASCO.png","width":772,"height":482,"caption":"Renal Cell Carcinoma Highlights- ASCO"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/90e3f864ebcfcaa34b1be0e9ae5909e1","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7f5e159702916007828000ba2479aa162e568daf1ea6bf5b637e8ed4c71407ce?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7f5e159702916007828000ba2479aa162e568daf1ea6bf5b637e8ed4c71407ce?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/anigam"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/25192143\/Renal-Cell-Carcinoma-Highlights-ASCO-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ASCO<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ASCO GU 2022<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Renal Cell Carcinoma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">ASCO<\/span>","<span class=\"advgb-post-tax-term\">ASCO GU 2022<\/span>","<span class=\"advgb-post-tax-term\">Oncology<\/span>","<span class=\"advgb-post-tax-term\">Renal Cell Carcinoma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Feb 25, 2022","modified":"Updated on Mar 10, 2022"},"absolute_dates_time":{"created":"Posted on Feb 25, 2022 7:22 pm","modified":"Updated on Mar 10, 2022 10:21 am"},"featured_img_caption":"Renal Cell Carcinoma Highlights- ASCO","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/16318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=16318"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/16318\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/16330"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=16318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=16318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=16318"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=16318"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=16318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}